Clinical trial of adjuvant peptide vaccine therapy for oral cancer研究代表者

我们使用这些肽的癌症疫苗接种疗法对口腔癌具有良好的耐受性。术后局部复发转移5例（腹膜播散1例，肺转移1例，颈淋巴结转移1例，局部复发2例，转移1例）。然而，没有腹膜播散的转移灶被移除，并且所有病例都使用这些肽继续疫苗接种治疗。在HLA-24（+）组中，ELISPOT检测显示URLC 10-、CDCA 1-和KOC 1-特异性CTL应答分别占HLA-24（+）组的88.2%、82.4%和52.9%。显示URLC 10和CDCA 1特异性CTL应答的患者分别显示更好的临床应答。结论：使用这些肽的V疫苗具有良好的耐受性，并且观察到可测量的免疫应答和抗肿瘤效果。这种疫苗诱导的免疫应答可以使头颈癌患者的预后更好

Our cancer vaccination therapy using these peptides was welltolerated for oral cancer . 5 patients showed a postoperative local recurrence and metastasis(peritoneal dissemination;1 case, lung metastasis;1 case , cervical lymph node metastasis; 2cases and local recurrence; 1case). However , metastatic foci without peritoneal disseminationwere removed and all cases are continued vaccination therapy using these peptides. In all ofcases, recurrence and/or metastasis are not recognized after treatment.In the HLA-24(+) group, ELISPOT assay indicated that the URLC10-, CDCA1-, andKOC1-specific CTL responses were observed after the vaccination in 88.2%, 82.4%, and 52.9%,of the HLA-24(+) group, respectively. The patients showing URLC10 and CDCA1 specificCTL responses revealed the better clinical response, respectively. Conclusions: V accination using these peptides was well tolerated, and measurable immuneresponses and antitumor efficacy are observed. The immune response induced by thisvaccination can make their prognosis better for head and neck cancer patients